Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coordinating Antibiotics, Test Development Could Shorten Approval Times, US FDA Says

Executive Summary

In a new draft guidance, the agency recommends antimicrobial drug developers and sponsors of antimicrobial susceptibility tests coordinate their regulatory submissions to get their products on the market together faster.

Advertisement

Related Content

Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity
UN Countries Make Bold Pledges On AMR, Including Funding For R&D Into New Drugs and Diagnostics

Topics

Advertisement
UsernamePublicRestriction

Register

MT103880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel